Key result
Drug-eluting balloons linked to ~57% lower 1-year major cardiovascular events vs. repeat DES in recurrent ISR.
Why the study?
Approximately 10-20% of patients with DES in-stent restenosis develop recurrent ISR, yet the optimal management strategy comparing drug-eluting balloons with repeated implantation of new-generation DES was unknown.
Does drug-eluting balloon angioplasty reduce 1-year major adverse cardiovascular events compared with repeated new-generation drug-eluting stent implantation in patients with recurrent drug-eluting stent in-stent restenosis?
Cohort (n=172)
Single-blind (QCA analyst blinded to clinical outcome)
No
Does drug-eluting balloon angioplasty reduce 1-year major adverse cardiovascular events compared with repeated new-generation drug-eluting stent implantation in patients with recurrent drug-eluting stent in-stent restenosis?
Answers are grounded in this paper and cite their sources.
In patients with recurrent DES in-stent restenosis, drug-eluting balloon angioplasty was associated with significantly lower 1-year MACE and target lesion revascularization rates compared with repeat new-generation DES implantation, particularly when avoiding a third or greater layer of stent metal.
OBJECTIVE: Approximately, 10-20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal management of recurrent DES-ISR is unknown. We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting balloons (DEB) to those with repeated implantation of new-generation DES. METHODS: A total of 172 patients with recurrent DES-ISR were enrolled and stratified into two cohorts: the repeated DES implantation (Re-DES) group and the DEB group. The primary endpoint was the 1-year incidence of major adverse cardiovascular events (MACE). RESULTS: Ninety-three patients treated with DEB and 79 patients with Re-DES implantation were analyzed. Both groups had comparable baseline characteristics. Lesser residual stenosis was achieved in the Re-DES group (11.3 ± 3.2% vs. 22.4 ± 4.3%; P = 0.00) than in the DEB group. However, the incidence of MACE and target lesion revascularization (TLR) were less in the DEB group (17.2% vs. 32.9%; P = 0.02 and 15.1% vs. 27.8%; P = 0.04, respectively). For the ≥3 metal-layered DES-ISR subgroup, DEB drastically reduced the incidences of MACE and TLR compared with Re-DES (20.0% vs. 57.9%; P = 0.02 and 16.0% vs. 47.4%; P = 0.04, respectively). Survival analysis demonstrated that MACE-free survival was significantly higher in the DEB group compared with the Re-DES group, whether the metal layers were ≥3 or 2. Multivariate analysis revealed that the risk factors of MACE were diabetes mellitus, ≥3 metal-layered DES ISR, and repeat DES deployment. CONCLUSIONS: For recurrent DES-ISR, DEB may improve clinical outcomes compared with Re-DES implantation, especially for ≥3 metal-layered DES-ISR.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) conducted a cohort in Recurrent drug-eluting stent in-stent restenosis (DES-ISR) (n=172). Drug-eluting balloon (DEB) angioplasty (paclitaxel-eluting balloon SeQuent Please) vs. Repeated implantation of new-generation drug-eluting stent (Re-DES: everolimus- or zotarolimus-eluting stents) was evaluated on 1-year incidence of major adverse cardiovascular events (MACE: composite of cardiovascular death, nonfatal myocardial infarction, ischemia-driven target lesion revascularization, and stent thrombosis) (HR 0.43, 95% CI 0.23-0.79, p=0.007). Drug-eluting balloon angioplasty reduced 1-year major cardiovascular events compared with repeat new-generation DES implantation in recurrent DES-ISR.
Synapse has enriched 10 related papers. Consider them for comparative context: